Antonieta Salud
Overview
Explore the profile of Antonieta Salud including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
54
Citations
976
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Xu C, Mannucci A, Esposito F, Oliveres H, Alonso-Orduna V, Alonso Orduna V, et al.
Clin Cancer Res
. 2025 Jan;
PMID: 39820673
PURPOSE EXONERATE (EXOsome and cell-free micro-RNAs of anti-EGFR ResistAnce) was an open-label, biomarker interventional study designed to develop, test, and validate a liquid biopsy predictive of progression-free survival (PFS), overall...
2.
Munavvar M, Bodtger U, Carus A, Cordovilla R, Naik S, Salud A, et al.
JCO Oncol Pract
. 2024 Dec;
:OP2400387.
PMID: 39689269
Malignant pleural effusion (MPE) is common in individuals with cancer and typically reflects advanced disease. Most cases are symptomatic, with dyspnea and pain having a severe effect on the patient's...
3.
Hidalgo I, Sorolla M, Sorolla A, Salud A, Parisi E
Int J Mol Sci
. 2024 Nov;
25(22).
PMID: 39596471
Secreted phospholipase 2 (sPLA2) is the largest family of phospholipase A2 (PLA2) enzymes with 11 mammalian isoforms. Each sPLA2 exhibits different localizations and specific properties, being involved in a very...
4.
Veas Rodriguez J, Prieto A, Vilaprinyo E, Bonet M, Diez M, Salud A, et al.
Crit Rev Oncol Hematol
. 2024 Aug;
202:104466.
PMID: 39127520
No abstract available.
5.
Veas Rodriguez J, Prieto A, Vilaprinyo E, Bonet M, Diez M, Salud A, et al.
Crit Rev Oncol Hematol
. 2024 Jun;
201:104416.
PMID: 38871262
Overall survival (OS) is the most meaningful endpoint in clinical trials. However, owing to their limitations, surrogate endpoints are commonly used and validation studies are required to assess their reliability....
6.
Marques M, Pont M, Hidalgo I, Sorolla M, Parisi E, Salud A, et al.
Int J Mol Sci
. 2023 Sep;
24(18).
PMID: 37762343
The sensitivity of pleural fluid (PF) analyses for the diagnosis of malignant pleural effusions (MPEs) is low to moderate. Knowledge about the pathobiology and molecular characteristics of this condition is...
7.
Pont M, Marques M, Sorolla M, Parisi E, Urdanibia I, Morales S, et al.
Cancers (Basel)
. 2023 Sep;
15(17).
PMID: 37686639
Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) technology has transformed oncology research in many ways. Breast cancer is the most prevalent malignancy globally and triple negative breast cancer (TNBC) is...
8.
Parisi E, Hidalgo I, Montal R, Pallise O, Tarragona J, Sorolla A, et al.
Int J Mol Sci
. 2023 Jul;
24(13).
PMID: 37446068
Metastasis is the leading cause of colorectal cancer (CRC)-related deaths. Therefore, the identification of accurate biomarkers predictive of metastasis is needed to better stratify high-risk patients to provide preferred management...
9.
Pesantez D, Ten Hoorn S, Machado I, Garcia-Albeniz X, Rodriguez-Salas N, Heredia-Soto V, et al.
J Natl Cancer Inst
. 2023 Jul;
115(12):1497-1505.
PMID: 37405857
Background: The results of the Grupo Español Multidisciplinar en Cáncer Digestivo (GEMCAD)-1402 phase II randomized trial suggested that adding aflibercept to modified fluorouracil, oxaliplatin, and leucovorin (mFOLFOX6) induction, followed by...
10.
Valladares-Ayerbes M, Garcia-Alfonso P, Munoz Luengo J, Pimentel Caceres P, Castillo Trujillo O, Vidal-Tocino R, et al.
Cancers (Basel)
. 2022 Dec;
14(24).
PMID: 36551560
The serial analysis of cell-free DNA (cfDNA) enables minimally invasive monitoring of tumor evolution, providing continuous genetic information. PERSEIDA was an observational, prospective study assessing the cfDNA (/) mutational status...